Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.86 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | BCHE | P06276 | 2/20 | 0.75 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.75 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.75 |
| ▸ | ACHE | P22303 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.75 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.75 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.71 |
| ▸ | RELA | Q04206 | 2/20 | 0.71 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Chloro Chalcone SCHEMBL197311 | 1.00 | MAOB (1.00) | MAOBCYP1B1MAPTLMNABCHE | |
| 4-Chloro Chalcone SCHEMBL197310 | 1.00 | MAOB (1.00) | MAOBCYP1B1MAPTLMNABCHE | |
| SCHEMBL196425 | 0.93 | CYP1B1 (1.00) | MAOBCYP1B1MAPTLMNABCHE | |
| SCHEMBL196424 | 0.93 | CYP1B1 (1.00) | MAOBCYP1B1MAPTLMNABCHE | |
| SCHEMBL10415521 | 0.93 | CYP1B1 (1.00) | MAOBCYP1B1MAPTLMNABCHE | |
| 4',4-Dichlorochalcone SCHEMBL659210 | 0.90 | MAOB (0.86) | MAOBCYP1B1MAPTTNFRSF1ACXCL12 | |
| 4',4-Dichlorochalcone SCHEMBL659211 | 0.90 | MAOB (0.86) | MAOBCYP1B1MAPTTNFRSF1ACXCL12 | |
| SCHEMBL9915665 | 0.90 | CYP1B1 (0.91) | MAOBCYP1B1MAPTLMNABCHE | |
| SCHEMBL8431772 | 0.90 | CYP1B1 (0.91) | MAOBCYP1B1MAPTLMNABCHE | |
| SCHEMBL657311 | 0.90 | MAOB (0.81) | MAOBCYP1B1MAPTLMNABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-4910303-A | Cataltyic reaction using N-alkylbis(2-hydroxyalkyl)amine | TEXACO CHEMICAL COMPANY (US) | 1990-03-20 | — | — | US | disclosed |
| US-3989708-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | MAOB 304/4885CYP1B1 26/4885MAPT 783/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | MAOB 335/4885CYP1B1 15/4885MAPT 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.